The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients
Open accessAbstract
OBJECTIVE: Phase III study to confirm a trend observed in a previous phase II study showing that a single dose of lenercept, human recombinant p55 tumor necrosis factor receptor-immunoglobulin G1 (TNFR55-IgG1) fusion protein, decreased mortality in patients with severe sepsis or early septic shock. DESIGN: Multicenter, double-blind, phase III, placebo-controlled, randomized study. SETTING: A total of 108 community and university-affiliated hospitals in the United States (60), Canada (6) and Europe (42). PATIENTS: A total of 1,342 patients were recruited who fulfilled the entry criteria within the 12-hr period preceding the study drug administration. INTERVENTION: After randomization, an intravenous dose of 0.125 mg/kg lenercept or placebo was given. The patient was monitored for up to 28 days, during which standard diagnostic, supportive, and therapeutic care was provided. MEASUREMENTS AND MAIN RESULTS: The primary outcome measure was 28-day all-cause mortality. Baseline characteristics were as follows: a total of 1,342 patients were randomized; 662 received lenercept and 680 received placebo. The mean age was 60.5 yrs (range, 17-96 yrs); 39% were female; 65% had medical admissions, 8% had scheduled surgical admissions, and 27% had unscheduled surgical admissions; 73% had severe sepsis without shock, and 27% had severe sepsis with early septic shock. Lenercept and placebo groups were similar at baseline with respect to demographic characteristics, simplified acute physiology score II-predicted mortality, profiles of clinical site of infection and microbiological documentation, number of dysfunctioning organs, and interleukin-6 (IL-6) plasma concentration. Lenercept pharmacokinetics were similar in severe sepsis and early septic shock patients. Tumor necrosis factor was bound in a stable manner to lenercept as reflected by the accumulation of total serum tumor necrosis factor alpha concentrations. There were 369 deaths, 177 on lenercept (27% mortality) and 192 on placebo (28% mortality). A one-sided Cochran-Armitage test, stratified by geographic region and baseline, predicted 28-day all-cause mortality (simplified acute physiology score II), gave a p value of .141 (one-sided). Lenercept treatment had no effect on incidence or resolution of organ dysfunctions. There was no evidence that lenercept was detrimental in the overall population. CONCLUSION: Lenercept had no significant effect on mortality in the study population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathophysiology Of Tumor Necrosis Factors
VASSALLI, P. (1992) · Annual Review of Immunology · doi:10.1146/annurev.immunol.10.1.411 · Cited by 1,920
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
Fisher, C. J., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E., Schein, R. M. H., & Benjamin, E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342603 · Cited by 1,241
Self-citationMohler, K. M., Torrance, D. S., Smith, C. A., Goodwin, R. G., Stremler, K. E., Fung, V. P., Madani, H., & Widmer, M. B. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.3.1548 · Cited by 832
Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
Zeni, F., Freeman, B., & Natanson, C. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00001 · Cited by 648
de Werra, I., Jaccard, C., Corradin, S. B., Chiolero, R., Yersin, B., Gallati, H., Assicot, M., Bohuon, C., Baumgartner, J.-D., Glauser, M. P., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199704000-00009 · Cited by 388
Abraham, E. (1997) · JAMA · doi:10.1001/jama.1997.03540430043031 · Cited by 379
Self-citationProtection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.
Ashkenazi, A., Marsters, S. A., Capon, D. J., Chamow, S. M., Figari, I. S., Pennica, D., Goeddel, D. V., Palladino, M. A., & Smith, D. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10535 · Cited by 275
Lesslauer, W., Tabuchi, H., Gentz, R., Brockhaus, M., Schlaeger, E. J., Grau, G., Piguet, P. F., Pointaire, P., Vassalli, P., & Loetscher, H. (1991) · European Journal of Immunology · doi:10.1002/eji.1830211134 · Cited by 237
Self-citationvan der Poll, T., & Lowry, S. F. (1995) · Shock · doi:10.1097/00024382-199501000-00001 · Cited by 230
Evans, T. J., Moyes, D., Carpenter, A., Martin, R., Loetscher, H., Lesslauer, W., & Cohen, J. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.6.2173 · Cited by 174
Self-citation
Cited by
Hotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J.-L. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.45 · Cited by 1,620
Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis
Wang, H., Liao, H., Ochani, M., Justiniani, M., Lin, X., Yang, L., Al-Abed, Y., Wang, H., Metz, C., Miller, E. J., et al. (2004) · Nature Medicine · doi:10.1038/nm1124 · Cited by 1,170
Reversing established sepsis with antagonists of endogenous high-mobility group box 1
Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H. E., Susarla, S. M., Ulloa, L., Wang, H., DiRaimo, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2434651100 · Cited by 1,126
Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome
Bhatia, M., & Moochhala, S. (2004) · The Journal of Pathology · doi:10.1002/path.1491 · Cited by 1,095
Russell, J. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra043632 · Cited by 1,048
Metadata
- Authors
- Abraham, E., Laterre, P.-F., Garbino, J., Pingleton, S., Butler, T., Dugernier, T., Margolis, B., Kudsk, K., Zimmerli, W., Anderson, P., Reynaert, M., Lew, D., Lesslauer, W., Cooper, S. P. P., Burdeska, A., Modi, M., Leighton, A., Salgo, M., & Van der Auwera, P.
- Venue
- Critical Care Medicine
- Published
- 2001-03
- Volume
- 29
- Issue
- 3
- Pages
- 503-510
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2091330377
- Cited by
- 293
- References
- 14
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. https://app.cochat.ai/papers/10.1097/00003246-200103000-00006
- The paper
- Abraham, E., Laterre, P.-F., Garbino, J., Pingleton, S., Butler, T., Dugernier, T., Margolis, B., Kudsk, K., Zimmerli, W., Anderson, P., Reynaert, M., Lew, D., Lesslauer, W., Cooper, S. P. P., Burdeska, A., Modi, M., Leighton, A., Salgo, M., & Van der Auwera, P. (2001). Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Critical Care Medicine. https://doi.org/10.1097/00003246-200103000-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.